#mainLogin {width : 700px;background: url(http://imaging.cmpmedica.com/all/gradient-grey-bg2.png) repeat-x bottom;border : 1px solid #cccccc;}#mainLogin h1 {font-size: 1.6em;color: rgb(255, 255, 255);background-color: #007882;padding : 5px;text-align:left;}.largeText {font-size : 1.4em;}#mainLogin ul {list-style-type: disc;list-style-position: outside;padding-left : 20px;}#mainLogin label {color:#666666;}#passwordLink {font-size : 12px;}#login {color:white;background-color:#144892;}td.left, td.right, .alert {padding : 12px;}td.right {border-left : 1px solid #cccccc;}
Welcome to OBGYN.net
This information is available by free membership.
FDA adds boxed warning to fezolinetant for rare serious liver injury
Published: December 17th 2024 | Updated: December 17th 2024The FDA has added a boxed warning for fezolinetant (VEOZAH; Astellas), highlighting the rare occurrence of serious liver injury in patients taking the menopause treatment.
Read More